These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 28382804

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Which is currently the best strategy for treatment of SFA in-stent restenosis?
    Elens M, Verbist J, Keirse K, Van Den Eynde W, Peeters P.
    J Cardiovasc Surg (Torino); 2014 Aug; 55(4):477-81. PubMed ID: 24941234
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The role for DCBs in the treatment of ISR.
    Bague N, Nasr B, Chaillou P, Costargent A, Gouailler-Vulcain F, Goueffic Y.
    J Cardiovasc Surg (Torino); 2016 Aug; 57(4):578-85. PubMed ID: 27102629
    [Abstract] [Full Text] [Related]

  • 7. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K, Fujii K, Kawasaki D, Shibuya M, Fukunaga M, Imanaka T, Tamaru H, Sumiyoshi A, Nishimura M, Horimatsu T, Saita T, Okada K, Kimura T, Honda Y, Fitzgerald PJ, Masuyama T, Ishihara M.
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [Abstract] [Full Text] [Related]

  • 8. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwälder U, Schwarz T, Noory E.
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G, Schroeder H, Albrecht T, Reimer P, Diehm N, Baeriswyl JL, Brechtel K, Speck U, Zeller T.
    J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
    [Abstract] [Full Text] [Related]

  • 10. Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
    Giannopoulos S, Kokkinidis DG, Jawaid O, Behan S, Hossain P, Alvandi B, Foley TR, Singh GD, Waldo SW, Armstrong EJ.
    Cardiovasc Revasc Med; 2020 Jun; 21(6):771-778. PubMed ID: 31761634
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
    Stavroulakis K, Schwindt A, Torsello G, Stachmann A, Hericks C, Bosiers MJ, Beropoulis E, Stahlhoff S, Bisdas T.
    J Endovasc Ther; 2017 Apr; 24(2):181-188. PubMed ID: 28008792
    [Abstract] [Full Text] [Related]

  • 13. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.
    Zeller T, Langhoff R, Rocha-Singh KJ, Jaff MR, Blessing E, Amann-Vesti B, Krzanowski M, Peeters P, Scheinert D, Torsello G, Sixt S, Tepe G, DEFINITIVE AR Investigators.
    Circ Cardiovasc Interv; 2017 Sep; 10(9):e004848. PubMed ID: 28916599
    [Abstract] [Full Text] [Related]

  • 14. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up.
    Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G, Tesorio T, Cota L, Popusoi G, Pucciarelli A, Esposito G, Trimarco B, Rubino P.
    JACC Cardiovasc Interv; 2014 Apr; 7(4):411-5. PubMed ID: 24630884
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: A single center experience (JET-SCE).
    Shammas NW, Shammas GA, Jones-Miller S, Shammas WJ, Bou-Dargham B, Shammas AN, Banerjee S, Rachwan RJ, Daher GE.
    Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):771-777. PubMed ID: 30420096
    [Abstract] [Full Text] [Related]

  • 16. Drug-eluting balloon catheters for lower limb peripheral arterial disease: the evidence to date.
    Barkat M, Torella F, Antoniou GA.
    Vasc Health Risk Manag; 2016 Oct; 12():199-208. PubMed ID: 27274265
    [Abstract] [Full Text] [Related]

  • 17. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Common Femoral Artery Atherosclerotic Disease.
    Stavroulakis K, Schwindt A, Torsello G, Beropoulis E, Stachmann A, Hericks C, Bollenberg L, Bisdas T.
    J Endovasc Ther; 2018 Feb; 25(1):92-99. PubMed ID: 29251204
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S, Liistro F, Angioli P, Ducci K, Falsini G, Porto I, Ricci L, Ventoruzzo G, Turini F, Bellandi G, Bolognese L.
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.